Id: acc0879
Group: 2sens
Protein: AKT
Gene Symbol: AKT1
Protein Id: P31749
Protein Name: AKT1_HUMAN
PTM: phosphorylation
Site: Tyr705
Site Sequence: --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Disease Category: Cancer
Disease: Ovarian Cancer
Disease Subtype:
Disease Cellline: HEY
Disease Info:
Drug: Cisplatin
Drug Info: "Cisplatin is a platinum-based chemotherapeutic agent widely used in the treatment of various malignancies, including ovarian, bladder, testicular, and non-small cell lung cancers, by forming DNA cross-links to interfere with replication and repair, thereby inhibiting cancer cell growth and proliferation."
Effect: inhibit
Effect Info: Phosphorylation of STAT3 at the Y705 site enhances cellular resistance to cisplatin by inhibiting ER stress-mediated autophagy.
Note:
Score: 5.0
Pubmed(PMID): 31597912
Sentence Index:
Sentence:

Sequence & Structure:

MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Completed metastatic prostate cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting breast neoplasm ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Completed triple-negative breast cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting breast cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Completed breast cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Terminated breast cancer ClinicalTrials
AKT1 AFURESERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting breast cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting breast cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting breast cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting prostate cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting prostate cancer ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed hepatocellular carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed head and neck squamous cell carcinoma ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 2 Active, not recruiting neoplasm of mature B-cells ClinicalTrials
AKT1 UPROSERTIB Serine/threonine-protein kinase AKT inhibitor 2 Terminated acute myeloid leukemia ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 2 Active, not recruiting adenocarcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed breast carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Terminated breast carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed adenosquamous lung carcinoma ClinicalTrials
AKT1 UPROSERTIB Serine/threonine-protein kinase AKT inhibitor 2 Completed breast carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed bronchoalveolar adenocarcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed diffuse large B-cell lymphoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Terminated diffuse large B-cell lymphoma ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 2 Terminated gastric adenocarcinoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

AKT1-Ser124
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1-Ser126
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1-Ser129
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1-Thr448
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
AKT1-Thr450
Cancer Intensity
BRCA
COAD -0.936
HGSC -1.526
ccRCC 0.252
GBM 0.594
HNSC
LUAD 0.617
LUSC
non_ccRCC
PDAC
UCEC 0.999
AKT1-Tyr315
Cancer Intensity
BRCA 0.788
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -1.125
LUSC 0.336
non_ccRCC
PDAC
UCEC
AKT1S1-Ser183
Cancer Intensity
BRCA 1.667
COAD 0.891
HGSC 0.725
ccRCC -1.189
GBM 0.792
HNSC 0.064
LUAD -0.194
LUSC -0.266
non_ccRCC -1.722
PDAC -0.879
UCEC 0.11
AKT1S1-Ser202
Cancer Intensity
BRCA -0.344
COAD -0.013
HGSC -2.725
ccRCC -0.093
GBM -0.249
HNSC 0.707
LUAD 0.324
LUSC 0.615
non_ccRCC 0.322
PDAC 0.379
UCEC 1.076
AKT1S1-Ser203
Cancer Intensity
BRCA -0.189
COAD 0.095
HGSC -2.902
ccRCC 0.277
GBM 0.142
HNSC 0.479
LUAD 0.265
LUSC 0.603
non_ccRCC 0.04
PDAC 0.419
UCEC 0.771
AKT1S1-Ser211
Cancer Intensity
BRCA -1.13
COAD 0.333
HGSC -2.178
ccRCC 0.627
GBM 0.09
HNSC 1.177
LUAD -0.47
LUSC 0.383
non_ccRCC
PDAC 0.715
UCEC 0.451
AKT1S1-Ser212
Cancer Intensity
BRCA -1.05
COAD 0.546
HGSC -2.08
ccRCC -0.197
GBM 0.641
HNSC 1.003
LUAD -0.628
LUSC 0.311
non_ccRCC
PDAC 0.36
UCEC 1.094
AKT1S1-Ser247
Cancer Intensity
BRCA
COAD -1.124
HGSC
ccRCC
GBM 0.791
HNSC 0.334
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1S1-Ser88
Cancer Intensity
BRCA -1.265
COAD -0.583
HGSC
ccRCC -0.267
GBM 0.344
HNSC 2.36
LUAD -0.052
LUSC 0.649
non_ccRCC -0.088
PDAC -0.187
UCEC -0.912
AKT1S1-Ser92
Cancer Intensity
BRCA -1.122
COAD -0.689
HGSC
ccRCC 0.068
GBM -0.037
HNSC 2.235
LUAD 0.28
LUSC 0.221
non_ccRCC -0.997
PDAC 0.777
UCEC -0.735
AKT1S1-Thr198
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.647
GBM
HNSC
LUAD -0.505
LUSC
non_ccRCC
PDAC
UCEC 1.152
AKT1S1-Thr246
Cancer Intensity
BRCA
COAD -0.468
HGSC 0.953
ccRCC
GBM -1.179
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.694
AKT1S1-Thr90
Cancer Intensity
BRCA
COAD 0.347
HGSC -1.784
ccRCC 0.431
GBM
HNSC 0.542
LUAD 0.465
LUSC
non_ccRCC
PDAC
UCEC
AKT1S1-Thr97
Cancer Intensity
BRCA 1.061
COAD -1.872
HGSC
ccRCC 0.814
GBM -0.592
HNSC 0.541
LUAD 0.201
LUSC
non_ccRCC
PDAC
UCEC -0.152

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - D Sepsis Acetylation 37211747
S 124 D Pancreatic ductal adenocarcinoma Phosphorylation 27014871
S 473 D Head and neck squamous cell carcinoma Phosphorylation 21281788
T 308 D Diabetes mellitus Phosphorylation 17272402 ;  20938636 ;  15919790
T 308 D Ovarian cancer/carcinoma Phosphorylation 20153512
T 308 D Head and neck squamous cell carcinoma Phosphorylation 21281788
T 308 D Type 2 diabetes Phosphorylation 15919790 ;  15919790
S 473 D Triple-negative breast cancer Phosphorylation 34077419
S 473 D Bladder cancer Phosphorylation 23799035
S 473 D Pancreatic cancer Phosphorylation 28363942 ;  15467756
- - D Oral squamous cell carcinoma Phosphorylation 23723304
- - D Laryngeal cancer Phosphorylation 23886414
- - D Myelodysplasia Phosphorylation 12529294
- - D Glioma/adult gliomas Phosphorylation 12839945
S 473 D Colon cancer Phosphorylation 35190555
S 473 D Oral squamous cell carcinoma Phosphorylation 31889370
T 554 N Ovarian clear cell carcinoma Phosphorylation 24299208
K 64 P Non-small cell lung cancer Methylation 30692626
S 129 P Lung cancer/carcinoma Phosphorylation 24008396
S 473 P Acute myeloid leukemia/acute myelogenous leukemia Phosphorylation 18056483
S 473 P Gastric cancer Phosphorylation 23969493 ;  23440515
S 473 P Ovarian cancer/carcinoma Phosphorylation 23877012
T 308 P Non-small cell lung cancer/carcinoma Phosphorylation 23091605
- - P Brain cancer Phosphorylation 12388552
- - P Embryonal central nervous system tumor Phosphorylation 16230398
- - P Glioblastoma Phosphorylation 23262078
- - P Acute monocytic leukemia Phosphorylation 24422998
S - P Colon cancer/carcinoma Phosphorylation 24464560
S 473 P Anaplastic astrocytoma Phosphorylation 23596468
S 473 P Esophageal squamous cell carcinoma Phosphorylation 23510069
S 473 P Non-small cell lung cancer/carcinoma Phosphorylation 23091605
S 473 P Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 23732709
S 473 P Breast cancer Phosphorylation 36632451
- - P Cancer SUMOylation 23884910
- - U Hepatocellular carcinoma Acetylation 31842909
- - U Papillary thyroid cancer Acetylation 37696385
K 426 U Breast cancer Acetylation 32499521
S 473 U Urethral cancer Phosphorylation 22975685
S 473 U Thymic carcinoma Phosphorylation 20597130
S 473 U Systemic lupus erythematosus Phosphorylation 23735868 ;  34522717 ;  23735868
S 473 U Squamous cell carcinoma Phosphorylation 21795477 ;  37109043
S 473 U Sjogren's syndrome Phosphorylation 34948236
S 473 U Breast cancer/tumor/carcinoma Phosphorylation 17545609 ;  12244301 ;  22476852
S 473 U Cancer Phosphorylation 21795477
S 473 U Cholangiocarcinoma Phosphorylation 37752233
S 473 U Colon cancer/carcinoma Phosphorylation 22975685
S 473 U Colorectal cancer Phosphorylation 37430297
S 473 U Diabetes mellitus Phosphorylation 35835217
S 473 U Glioma Phosphorylation 33820494
S 473 U HER2-positive breast cancer Phosphorylation 36314765
S 473 U Kidney cancer Phosphorylation 12649200 ;  12649200 ;  22580611
S 473 U Liver cancer Phosphorylation 15684384
S 473 U Lymphocytic leukemia Phosphorylation 20576813
S 473 U Melanoma Phosphorylation 19996208 ;  12499277 ;  12499277 ;  19996208 ;  12499277
S 473 U Neuroblastoma Phosphorylation 17234785
S 473 U Non-small cell squamous cell lung carcinoma Phosphorylation 20008839
S 473 U Obesity Phosphorylation 35413055
S 473 U Ovarian cancer Phosphorylation 15208673
S 473 U Ovarian epithelial carcinoma Phosphorylation 32194423
S 473 U Pancreatic cancer Phosphorylation 15467756 ;  28363942
S 473 U Parkinson's disease Phosphorylation 19800394 ;  19800394 ;  21658387
S 473 U Renal cancer/carcinoma Phosphorylation 19118035 ;  16247451 ;  12649200
T 308 U Breast cancer Phosphorylation 33571243
T 308 U Chronic lymphocytic leukemia Phosphorylation 16940331
T 308 U Melanoma Phosphorylation 19996208
T 308 U Multiple myeloma Phosphorylation 37781194
T 308 U Neuroblastoma Phosphorylation 17234785
T 308 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 26676747
T 308 U Rhabdomyosarcoma Phosphorylation 17848913
T 450 U Cholangiocarcinoma Phosphorylation 35625759
T 308 U Acute myeloid leukemia/acute myelogenous leukemia Phosphorylation 12750723
T 308 U Cholangiocarcinoma Phosphorylation 37752233
T 308 U Lymphocytic leukemia Phosphorylation 20576813
T 308 U Obesity Phosphorylation 35413055
T 308 U Sjogren's syndrome Phosphorylation 34948236
T 308 U Endometrial cancer Phosphorylation 35253622
T 308 U Esophageal squamous cell carcinoma Phosphorylation 36995521
Y 176 U Breast cancer/tumor/carcinoma Phosphorylation 20333297
Y 176 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 22322295
- - U Tongue cancer Phosphorylation 37132640
- - U Epithelial ovarian cancer Phosphorylation 35105347
- - U Urothelial bladder cancer Phosphorylation 35691981
- - U Gastric cancer Phosphorylation 36604355
- - U Colorectal cancer Phosphorylation 35110545
- - U Pancreatic cancer Phosphorylation 31765735
- - U Marek's disease Phosphorylation 35795905
- - U Renal cell carcinoma Phosphorylation 34257606
S 473 U Cancer Phosphorylation 34767444
- - U Gastric cancer Phosphorylation 23898095
- - U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 23785446
- - U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 10853013
- - U Cervical cancer/carcinoma Phosphorylation 10853013
- - U Thyroid cancer Phosphorylation 12788904
- - U Endometrial cancer Phosphorylation 12888921
S 473 U Acute myeloid leukemia/acute myelogenous leukemia Phosphorylation 15289327
S 473 U Breast cancer Phosphorylation 17545609 ;  12244301 ;  12244301 ;  17545609 ;  21743495 ;  30413706
S 473 U Chronic lymphocytic leukemia Phosphorylation 16940331
S 473 U Esophageal squamous cell carcinoma Phosphorylation 31897228
S 473 U Gallbladder cancer Phosphorylation 33407730
S 473 U Hepatocellular carcinoma Phosphorylation 37573318 ;  36348350
S 473 U Multiple myeloma Phosphorylation 37781194
S 473 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 15467756 ;  21474066 ;  28363942
S 473 U Rhabdomyosarcoma Phosphorylation 17848913
S 473 U Synovial sarcoma Phosphorylation 35556229
S 473 U Cervical cancer Phosphorylation 32047568
S 473 U Osteosarcoma Phosphorylation 34476004
S 473 U Uveal melanoma Phosphorylation 34918581

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: